Pila Pharma AB (publ)

Stockholm Stock Exchange PILA.ST

Pila Pharma AB (publ) Net Income for the year ending December 31, 2023: USD -980.09 K

Pila Pharma AB (publ) Net Income is USD -980.09 K for the year ending December 31, 2023, a 77.02% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Pila Pharma AB (publ) Net Income for the year ending December 31, 2022 was USD -4.27 M, a -54.01% change year over year.
Pila Pharma AB (publ) Net Income for the year ending December 31, 2021 was USD -2.77 M, a -115.89% change year over year.
Pila Pharma AB (publ) Net Income for the year ending December 31, 2020 was USD -1.28 M, a 4.47% change year over year.
Pila Pharma AB (publ) Net Income for the year ending December 31, 2019 was USD -1.34 M, a -113.09% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

Stockholm Stock Exchange: PILA.ST

Pila Pharma AB (publ)

CEO	Mr. Gustav Hanghoj Gram
IPO Date	July 15, 2021
Location	Sweden
Headquarters	VAestergatan 1
Employees	1
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Vaccines

Description

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.

Key trends

Past 5 years